论文部分内容阅读
目的探讨经导管肝动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)联合索拉非尼治疗肝细胞癌临床疗效。方法对50例肝细胞癌患者的临床资料进行回顾性分析。50例中单纯行TACE治疗28例、TACE治疗联合索拉非尼22例。通过比较两组间疾病控制率、无进展生存时间,2年生存率差异等来评价治疗效果。结果联合治疗组在疾病控制率、无进展生存时间及2年生存率均优于单纯TACE治疗组,差异具有统计学意义。结论 TACE联合索拉非尼治疗肝细胞癌较单纯TACE能够提高有效率,延长无进展生存时间及患者生存期,是一种更为有效的治疗方法。
Objective To investigate the clinical efficacy of transcatheter arterial chemoembolization (TACE) combined with sorafenib in the treatment of hepatocellular carcinoma. Methods The clinical data of 50 patients with hepatocellular carcinoma were retrospectively analyzed. Twenty patients were treated with TACE alone in 50 cases and 22 patients with TACE combined with sorafenib. By comparing the two groups disease control rate, progression-free survival time, 2-year survival rate differences to evaluate the treatment effect. Results The rate of disease control, progression-free survival and 2-year survival rate in the combined treatment group were better than those in the TACE alone group, the difference was statistically significant. Conclusion TACE combined with sorafenib treatment of hepatocellular carcinoma than simple TACE can improve the efficiency and prolong the progression-free survival time and patient survival, is a more effective treatment.